Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (February 2020)
23 slides from Biocon's investor presentation, Feb 10, 2020
Slide 1: Covering letter to stock exchanges
Biocon Biocon Limited 20th KM Hosur Road Electronics City Bangalore 560 100, India 91 80 2808 2808 F91 80 2852 3423, CIN : 124234KA1978PLC003417 February 10, 2020 Gearaa iacareore To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services
Slide 2: Biocon Limited Investor Presentation February 2020
Biocon Limited BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM INVESTOR PRESENTATION February 2020 1
Slide 3: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 4: Committed to Affordable Access
Committed to Affordable Access Aiming to develop products that can potentially benefit a billion patients 3
Slide 5: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978- 2000- 2005- 2010- 2016- 1999 2004 2009 2015 2019 2018 An Transforming Building the Base Strategic Global Commercialized Poised for Enzymes into a Business and Alliance with Biosimilars for Global Company Biopharma Expertise in Mylan for Diabetes & Imp
Slide 6: Key Innovations: Making a Difference
Key Innovations: Making a Difference Ogivri™, first biosimilar Trastuzumab approved Launched by US FDA Ogivri™, biosimilar Second Novel Trastuzumab in Biologic (Insulin Glargine Launches US, EU, prefilled disposable KRABEVA®, Australia, First Novel pen) biosimilar Canada Bevacizumab in India Biologi
Slide 7: Financial Highlights
FINANCIAL HIGHLIGHTS 6
Slide 8: Financial Summary
Financial Summary All Figures in ₹ Million except % Growth Particulars Q3 FY20 Q3 FY19 Growth 9M FY20 9M FY19 (%) Revenue 17,839 15,664 14% 48,845 41,066 19% EBITDA 4,800 4,063 18% 13,830 11,069 25% Net Profit# 2,249 2,117 6% 6,366 5,154 24% R&D Expenses in 1,314 767 71% 3,144 1,978 59% P&L Gross R&
Slide 9: Revenue Highlights
Revenue Highlights All Figures in ₹ Million except % Particulars by segment Q3 FY20 Q3 FY19 Growth 9M FY20 9M FY19 Growth - Small Molecules 5,438 4,689 16% 15,530 13,009 19% - Biologics 5,882 4,486 31% 15,939 10,658 50% - Branded Formulations 1,573 2,122 (26)% 4,190 5,234 (20)% - Syngene (Research S
Slide 10: Key Financial Metrics
Key Financial Metrics All Figures in ₹ Million except % FY19 FY 20 Particulars Q3 9M FY19 Q4 Q1 Q2 Q3 9M FY20 SEGMENT REVENUE a. Small Molecules 4,689 13,099 4,719 4,796 5,296 5,438 15,530 b. Biologics 4,486 10,658 4,511 4,896 5,161 5,882 15,939 c. Branded Formulations 2,122 5,234 1,330 1,334 1,283
Slide 11: Business Segments
BUSINESS SEGMENTS 10
Slide 12: Our Growth Verticals
Our Growth Verticals Biosimilars Small Molecules Branded Formulations Differentiated APIs & Generic GROWTH Finished Dosage Formulations Business in India & VERTICALS Overseas Novel Biologics Research Services 11
Slide 13: Small Molecules APIs & Generic Formulations
Small Molecules APIs & Generic Formulations Differentiated API Portfolio Current Constituents Product Portfolio leverages core Portfolio fermentation technology strengths Simvastatin, Pravastatin, Atorvastatin, Statins Among world’s largest manufacturers of Rosuvastatin, & Fluvastatin. statins & imm
Slide 14: Biologics: Biosimilars & Novel Biologics
Biologics Biosimilars & Novel Biologics Novel Biologics Biosimilars Positioned among early Creating market leadership wave of entrants with in Innovation e.g., Insulin multiple biosimilars Tregopil, Itolizumab commercialized globally. 15+ years of experience is developing biologics. Pipeline include
Slide 15: Biocon Biologics: The Four Pillars
Biocon Biologics Transforming Healthcare, Transforming Lives Vision: “Most Inspiring Global Leader in Biologics” delivering affordable access to innovative and inclusive healthcare solutions, transforming patient lives. Implement strategic initiatives going beyond the product in our aspiration to re
Slide 16: Biocon Biologics Global Product Portfolio
Biocon Biologics Global Product Portfolio PIPLELINE OF 28 M O L E C U L E S BIOCON BIOLOGICS is independently developing many biosimilar assets With MYLAN, 11 biosimilars being co- developed for global markets With SANDOZ, set of next-gen immunology, oncology biosimilars being co-developed for globa
Slide 17: Biocon – Mylan Partnered Product Pipeline
Biocon – Mylan Partnered Product Pipeline Early mover in first wave of biosimilar launches in the next 3–5 years THERAPEUTIC STATUS MOLECULE AREA US EU MoW Launched in Australia, Canada & Emerging Trastuzumab Markets. Biocon’s strong development & Pegfilgrastim Approved in Canada and Australia manuf
Slide 18: Biocon - Sandoz exclusive partnership
Biocon - Sandoz exclusive partnership: Co-development of next-generation biosimilars Shared responsibility for… Broader Biocon participation in end-to-end development Development and commercialization Manufacturing Global regulatory approvals Various assets are in early stage development stage for C
Slide 19: Biocon Biologics: Manufacturing
Biocon Biologics: Manufacturing Global scale, cost competitive, complex manufacturing Global Scale Manufacturing Capabilities in India State-of-the-art manufacturing facilities – mammalian & microbial Facilities conform to most stringent cGMP guidelines Regulatory Approvals - EMA, US FDA, Health Can
Slide 20: Branded Formulations
Branded Formulations Now aligned with Biologics growth strategy Specialty business with regional ambitions; strong value builder for Biocon. Biologics-led specialty products focused on chronic therapy areas. Comprehensive offering of products, patient and physician support programs INDIA UAE India’s
Slide 21: Novel Molecules: Diabetes, Inflammation & Immuno-oncology
Novel Molecules Focused on Diabetes, Inflammation & Immuno-oncology Insulin Tregopil (In-house program) India Phase II/III in First-in-Class Oral, Prandial Insulin T2D ongoing DIABETES • Liver specific- portal delivery, Weight neutral • Pivotal Phase II/III clinical study in T2DM patients in India o
Slide 22: Research Services (Syngene)
Research Services (Syngene) A global CRO company delivering innovative scientific solutions. End-to-end discovery, development and manufacturing capabilities with focus on novel molecular entities Offers an integrated drug discovery, development and manufacturing platform for both small and large mo
Slide 23: Questions
Questions INVESTOR RELATIONS CONTACT: Saurabh Paliwal Tel : +91 80 6775 2040 Email: investor.relations@biocon.com 22